Given that immune thrombocytopenia (induced by anti-platelet treatment) can ameliorate inflammatory arthritis, we hypothesized that the ameliorative effects of anti-CD44 treatment in inflammatory arthritis could potentially be mediated by their ability to cause thrombocytopenia. This evidence concerns the gene CD44 and autoimmune thrombocytopenic purpura.